SeQuent® Please – The visionary way to treat vascular stenosis
B. Braun Vascular Systems presents the first Drug Eluting Balloon for PTCA, based on a polymer-free carrier matrix. This most innovative product is the result of our sustained research for new options and improvements in the field of coronary angioplasty. Clinically proven, it offers completely new procedural options to treat vascular stenoses since the drug elution does not require a stent platform.
patient information
Coronary artery disease and treatment options Within the following sites we would like to answer some of your questions on coronary artery disease (CAD), the diagnostic procedure and state of the art treatment options. more >>
latest news
B. Braun Germany – January 27, 2010 MEDRAD and B. Braun Melsungen AG Collaborate to Promote Breakthrough Medical Treatment for Cardiovascular Disease Melsungen (Germany). MEDRAD, Inc. WARRENDALE, Pa., has entered into a co-marketing and trademark license agreement with B. Braun Melsungen AG to promote the Paccocath® technology, a unique and clinically tested technology used to treat blocked vessels without stenting. The Paccocath technology has been shown in multiple clinical trials to keep the artery open wider (reduce late lumen loss) over time in patients with Peripheral Arterial Disease and Coronary Artery Disease (CAD). more (PDF 27 KB) >>
The above-mentioned product may not be registered in your country. Please check your local B. Braun website or contact your local B. Braun partner.
Contact
B. Braun Melsungen AG
Vascular Systems
Sieversufer 8
12359 Berlin
Germany
Tel. +49 30 68 98 97-0
Fax +49 30 68 98 97-30
E-Mail: vascular.systems@bbraun.com
Potential cost savings with innovative medical devices 2008
The Spectaris study analyses and demonstrates potential cost savings based on the example of selected innovative medical devices. The intention is to save costs combined with a more effective treatment. You will find the potential cost savings with SeQuent® Please on pages 48 to 51.
